Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Transfers Animal Health Products to Meiji Seika
November 25, 2002
- Sankyo: Sales, Profits Up Due to Export of Mevalotin, Overseas Sales
November 25, 2002
- Ube to Expand Production of Drug Intermediates, Bulk Chemicals
November 25, 2002
- 10 of 14 Top Drugmakers Report Increase in Sales in 1st Half
November 25, 2002
- Priority Order Proposed for Science, Technology-related Budgets
November 25, 2002
- Amino Acids to Remain Core of Ajinomoto's Pharma Business
November 25, 2002
- Meet the Leaders (11)
November 25, 2002
- REGULATORY NEWS IN BRIEF
November 25, 2002
- Sawai: Consolidated Sales Up 12.7% to \9,772 Mil.
November 25, 2002
- OTC NEWS IN BRIEF
November 25, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 25, 2002
- ACCJ Mounts "value of Medical Technology" PR Campaign
November 25, 2002
- WORLD NEWS IN BRIEF
November 25, 2002
- Tokai Univ. Researchers Start Up GenoDive Pharma
November 25, 2002
- Asahi Kasei: Health Care Sales Up 6.3% to \52.1 Bil.
November 25, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 25, 2002
- Teijin: Bonalon to Spur Business in 2nd Half
November 25, 2002
- PRESS SEMINAR
November 25, 2002
- Kyowa Hakko: Drug Sales Down 0.6% to \71.4 Bil.
November 25, 2002
- Kowa to Codevelop Arteriosclerosis Drugs with GENFIT of France
November 18, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…